ADiTx Therapeutics Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADiTx Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADiTx Therapeutics stock.
View analyst ratings for ADiTx Therapeutics or view top-rated stocks.

Wall Street analysts have given ADiTx Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ADiTx Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ADiTx Therapeutics saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 543,100 shares, an increase of 18.5% from the May 13th total of 458,300 shares. Based on an average trading volume of 291,500 shares, the short-interest ratio is currently 1.9 days. Currently, 4.9% of the shares of the stock are sold short.
View ADiTx Therapeutics' Short Interest.

ADiTx Therapeutics, Inc. (NASDAQ:ADTX) announced its earnings results on Tuesday, May, 11th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.25.
View ADiTx Therapeutics' earnings history.

Some companies that are related to ADiTx Therapeutics include Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), China Health Industries (CHHE), Diadexus (DDXSQ), ERBA Diagnostics (ERBA), GelStat (GSAC), Global Future City (FTCY), Imagenetix (IAGX), Immune Therapeutics (IMUN), Interpharm (IPAH) and Inyx (IYXI).
View all of ADTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADiTx Therapeutics investors own include Tesla (TSLA), Dynavax Technologies (DVAX), The Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Square (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS).

ADiTx Therapeutics trades on the NASDAQ under the ticker symbol "ADTX."

ADiTx Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.00%), Virtu Financial LLC (0.00%), Northern Trust Corp (0.00%) and XTX Topco Ltd (0.00%). Company insiders that own ADiTx Therapeutics stock include Corinne Pankovcin, Shahrokh Shabahang and Thomas J Farley.
View institutional ownership trends for ADiTx Therapeutics.

ADTX stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Virtu Financial LLC, Northern Trust Corp, and XTX Topco Ltd. Company insiders that have bought ADiTx Therapeutics stock in the last two years include Corinne Pankovcin, Shahrokh Shabahang, and Thomas J Farley.
View insider buying and selling activity for ADiTx Therapeutics or or view top insider-buying stocks.

Shares of ADTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADTX stock can currently be purchased for approximately $2.73.

ADiTx Therapeutics employs 43 workers across the globe.

The official website for ADiTx Therapeutics is www.aditxt.com.

ADiTx Therapeutics is headquartered at 2569 WYANDOTTE ST. SUITE 101, MOUNTAIN CA, 94043.

ADiTx Therapeutics' mailing address is 2569 WYANDOTTE ST. SUITE 101, MOUNTAIN CA, 94043. The company can be reached via phone at 650-870-1200.